Medtronic Executive Thompson Kweli Form 3 Filing - Equity Holdings Disclosure

This Form 3 filing discloses the initial statement of beneficial ownership of Medtronic plc (MDT) securities by Thompson Kweli, Executive Vice President & President of Neuroscience. The filing reports ownership of 30,017.737 ordinary shares, including 6,549 performance stock units that vested on April 24, 2026, and various restricted stock units with vesting dates through July 2028. Additionally, the filing discloses multiple stock option grants dating from 2017 to 2026, with exercise prices ranging from $74.67 to $131.26 and expiration dates extending to 2035. Performance share units are also reported with vesting contingent on achievement of performance metrics, potentially resulting in 0-9,911 shares depending on performance outcomes. The filing was signed by attorney-in-fact Patricia Walesiewicz on June 26, 2026, for the period ending June 18, 2026.